Significant predictors of 28-day mortality in critically ill patients with systemic sclerosis include male sex and BMI.

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

Background Systemic sclerosis, also known as scleroderma, is a complex, multi-organ disease which causes substantial and progressive fibrosis of the skin and internal organs, including the heart and ...

Scleroderma is a rare autoimmune disease involving an overproduction of the protein collagen. Linear scleroderma usually begins as a streak of hardened, waxy, discolored skin on the forehead, an arm, ...

Scleroderma is an autoimmune condition that causes the skin to become tight and hard. This can change facial appearance, such as the mouth becoming smaller, and affect internal organs. With ...

Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials Histone 3 (H3) K27M–mutant diffuse ...

To run a successful business, we bring together a diverse group of people with different skill sets to cover all areas of the business. This results in people who might have very different values and ...

Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

Systemic sclerosis (SSc) is a rare autoimmune disease that can harden the skin, impair blood flow, and damage internal organs such as the lungs and kidneys. But no two patients experience the disease ...

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...

Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational allogeneic CAR-T therapy, ALLO-329, for three autoimmune ...